Citrullinated peptides as drug candidates for rheumatoid arthritis

瓜氨酸化肽作为类风湿性关节炎的候选药物

阅读:2

Abstract

Rheumatoid arthritis (RA) involves a breakdown of immune tolerance to citrullinated proteins, leading to chronic inflammation and joint damage. Despite advances in treatment, achieving long-term remission remains a major challenge. Restoring immune tolerance to citrullinated proteins represents a promising strategy to halt disease progression and establish lasting remission. This review examines the potential of using citrullinated proteins or peptides to reestablish immune tolerance in RA. It explores the potential role of anti-citrullinated protein antibodies (ACPAs) in disease pathology and how utilizing or targeting specific citrullinated antigens could modulate immune responses. The review also highlights the therapeutic relevance of altering T and B cell function to regulate immune state. We explore mechanisms through which tolerance can be induced, including the use of citrullinated peptides to promote regulatory T (Treg) cell expansion and alter pathogenic B cell subsets. Emerging strategies aimed at re-educating the immune system are discussed, focusing on their potential to provide effective and durable treatment outcomes. These tolerance-based approaches are evaluated for their capacity to shift the immune response away from autoimmunity and towards sustained remission.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。